- Ozempic is an FDA-approved branded drug product. A compounded semaglutide preparation follows a different pharmacy and regulatory pathway.
- FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
- Published evidence must be read in the context of the product, regimen, population, comparator, and follow-up studied.
- A comparison article cannot tell you to switch, convert, or select a treatment. A licensed provider makes that decision when clinically appropriate.
Regulatory review is product-specific
Ozempic is an FDA-approved Novo Nordisk drug product. A compounded semaglutide preparation is prepared by a compounding pharmacy in a prescription context. FDA says compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
That distinction describes evidence and oversight pathways. It does not establish a conclusion about a particular prescription, pharmacy, or patient. FDA also tells patients to obtain a prescription from a doctor and fill it at a state-licensed pharmacy.
Labeling and prescription context
An approved product carries product-specific labeling reviewed through the approval pathway. A compounded preparation has a prescription label and dispensing-pharmacy instructions. Read the actual label you receive and direct questions to the licensed provider and pharmacy connected to that prescription.
Do not use comparison copy to choose a dose, calculate a conversion, change products, or decide when to begin or stop treatment. A licensed healthcare provider makes an independent prescribing decision when clinically appropriate.
Evidence provenance matters
When you read a study, identify the studied product, regimen, population, comparator, and duration. A result from a branded-product trial answers a question about that study and its participants. It does not establish a result for a compounded preparation or for an individual reader.
FDA’s warnings about unapproved GLP-1 products also show why source and pharmacy questions matter. FDA has described risks including mislabeled products and dosing errors. This article does not infer a Kind MD-specific violation, ingredient, formulation, or outcome.
Questions for a provider and pharmacy
- Which product and pharmacy are being discussed in my prescription?
- What evidence applies to that product and what evidence does not?
- What does my label say, and who should answer questions about it?
- What clinical factors does my provider need before making a prescribing decision?
Kind MD is a telehealth platform that connects eligible patients with licensed healthcare providers who may prescribe compounded semaglutide or tirzepatide when clinically appropriate. Kind MD works with licensed U.S. pharmacies. The dispensing pharmacy and applicable oversight may vary by prescription and state.
Want a provider-led discussion?
Start with information for a licensed provider to review.
Take the Free Quiz →